PDF herunterladen
Exp Clin Endocrinol Diabetes 2014; 122(05): 277-280
DOI: 10.1055/s-0034-1374585
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Association Between Endogenous Secretory Receptor for Advanced Glycation-end Products (esRAGE) and Carotid Intima-media Thickness in Type 2 Diabetes

Autoren

  • X. Lin   †

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • X. Chen   †

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • J. Ye

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • Q. Li

    2   Department of Research Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • J. Zhou

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • X. Wu

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • Y. Huang

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • X. Li

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • Y. Shi

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • S. Li

    3   Department of Ultrasonography, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • L. Li

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China

  • H. Cai

    1   Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China
Weitere Informationen

Publikationsverlauf

received 23. August 2013
first decision 21. Februar 2014

accepted 28. März 2014

Publikationsdatum:
16. Mai 2014 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background:

Advanced glycation end products (AGEs) contribute to vascular complications in type 2 diabetes (T2DM). Endogenous secretory receptor for advanced glycation end products (esRAGE) may inhibit the pathological effects of AGEs in T2DM vascular complications.

Objectives:

To investigate the relationship between esRAGE and diabetic carotid atherosclerosis, using carotid intima-media thickness (cIMT); and to determine if esRAGE influences levels of inflammatory cytokines (tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6)).

Methods:

Prospective observational study in 308 T2DM subjects (149 men and 159 women). An echotomographic system was used by a blinded operator to measure cIMT. Patients were divided into 2 groups according to cIMT. Body mass index was calculated and serum lipids were measured by an autoanalyzer. Enzyme-linked immunosorbent assays (ELISA) were used to detect serum esRAGE, TNF-α, and IL-6 levels.

Results:

Patients with a cIMT≥0.9 mm were older (P<0.0001), had more smokers (P=0.01), had a higher systolic blood pressure (SBP) (P<0.0001), and had lower HDL-C levels (P=0.01). esRAGE was lower in patients with a cIMT ≥0.9 mm (0.231±0.135 vs. 0.343±0.164, P<0.0001), while TNF-α levels were elevated (83.68±55.27 vs. 65.71±45.91, P=0.002). There was no difference in IL-6 levels between the 2 groups. Univariate analyses showed that age, T2DM duration, SBP, HDL-C, esRAGE and TNF-α were associated with cIMT. Multivariate analysis showed that age, SBP, HDL-C, smoking and esRAGE levels were independently associated with cIMT, but not TNF-α.

Conclusions:

This study demonstrated that circulating esRAGE levels are independently associated with smaller cIMT in T2DM patients.

Key words

endogenous secretory receptor for advanced ­glycation end-products - Tumor necrosis factor alpha - Interleukin 6 - Atherosclerosis - Diabetes mellitus

† Equal contributors


 

  • References

  • 1 Klein R, Klein BE, Moss SE et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Archives of internal medicine 1994; 154: 2169-2178
    CrossrefSuche in Google Scholar
  • 2 Bash LD, Selvin E, Steffes M et al. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Archives of internal medicine 2008; 168: 2440-2447
    CrossrefSuche in Google Scholar
  • 3 Hemmingsen B, Lund SS, Gluud C et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. The Cochrane database of systematic reviews 2013; 11 CD008143
    Suche in Google Scholar
  • 4 Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circulation research 2004; 95: 233-238
    CrossrefSuche in Google Scholar
  • 5 Stern DM, Yan SD, Yan SF et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing research reviews 2002; 1: 1-15
    CrossrefSuche in Google Scholar
  • 6 Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. The New England journal of medicine 1988; 318: 1315-1321
    CrossrefSuche in Google Scholar
  • 7 Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circulation research 2010; 106: 842-853
    CrossrefSuche in Google Scholar
  • 8 Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Laboratory investigation; a journal of technical methods and pathology 1994; 70: 138-151
    Suche in Google Scholar
  • 9 Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovascular research 2004; 63: 582-592
    CrossrefSuche in Google Scholar
  • 10 Kaplan M, Aviram M, Hayek T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacology & therapeutics 2012; 136: 175-185
    CrossrefSuche in Google Scholar
  • 11 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England journal of medicine 2005; 352: 1685-1695
    CrossrefSuche in Google Scholar
  • 12 Eckel RH, Wassef M, Chait A et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 2002; 105: e138-e143
    CrossrefSuche in Google Scholar
  • 13 Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13
    CrossrefPubMedSuche in Google Scholar
  • 14 Yonekura H, Yamamoto Y, Sakurai S et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. The Biochemical journal 2003; 370: 1097-1109
    CrossrefSuche in Google Scholar
  • 15 Shoji T, Koyama H, Morioka T et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 2006; 55: 2245-2255
    CrossrefSuche in Google Scholar
  • 16 Katakami N, Matsuhisa M, Kaneto H et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes care 2005; 28: 2716-2721
    CrossrefSuche in Google Scholar
  • 17 Choi KM, Yoo HJ, Kim HY et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. International journal of cardiology 2009; 132: 96-101
    CrossrefSuche in Google Scholar
  • 18 Humpert PM, Djuric Z, Kopf S et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovascular diabetology 2007; 6: 9
    CrossrefSuche in Google Scholar
  • 19 Katakami N, Matsuhisa M, Kaneto H et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diabetes & vascular disease research: official journal of the International Society of Diabetes and Vascular Disease 2008; 5: 190-197
    CrossrefSuche in Google Scholar
  • 20 Koyama H, Shoji T, Yokoyama H et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 2005; 25: 2587-2593
    CrossrefSuche in Google Scholar
  • 21 Piarulli F, Lapolla A, Ragazzi E et al. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. Atherosclerosis 2013; 226: 252-257
    CrossrefSuche in Google Scholar
  • 22 Aminbakhsh A, Mancini GB. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clinical and investigative medicine Medecine clinique et experimentale 1999; 22: 149-157
    Suche in Google Scholar
  • 23 Mancia G, De Backer G, Dominiczak A et al. 2007; Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension 2007; 25: 1105-1187
    CrossrefSuche in Google Scholar
  • 24 Liu LS. Writing Group of Chinese Guidelines for the Management of H. [2010 Chinese guidelines for the management of hypertension]. Zhonghua xin xue guan bing za zhi 2011; 39: 579-615
    Suche in Google Scholar
  • 25 Koyama H, Shoji T, Fukumoto S et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arteriosclerosis, thrombosis, and vascular biology 2007; 27: 147-153
    CrossrefSuche in Google Scholar
  • 26 Lu L, Pu LJ, Zhang Q et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009; 206: 540-545
    CrossrefPubMedSuche in Google Scholar
  • 27 Blackburn P, Lemieux I, Lamarche B et al. Effect of type 2 diabetes on various electrophoretic characteristics of low-density lipoprotein particles in women. Diabetologia 2004; 47: 2114-2117
    CrossrefSuche in Google Scholar
  • 28 Mehta JL, Chen J, Hermonat PL et al. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovascular research 2006; 69: 36-45
    CrossrefSuche in Google Scholar
  • 29 Feng B, Xu L, Wang H et al. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochimica et biophysica acta 2011; 1812: 1130-1137
    CrossrefSuche in Google Scholar
  • 30 Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. International journal of cardiology 2010; 142: 273-278
    CrossrefSuche in Google Scholar
  • 31 Li F, Cai Z, Chen F et al. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic research in cardiology 2012; 107: 306
    CrossrefSuche in Google Scholar